Advertisement

Prevalence and outcomes of anemia in cancer: a systematic review of the literature

      Abstract

      Anemia is common in patients with cancer. This systematic literature review of reports published in 1966 through February 2003 identified the prevalence of anemia in specific cancers and assessed the impact of anemia on survival and quality of life (QOL). Studies about chemotherapy-induced anemia were excluded. Anemia prevalence varied widely; most studies found that between 30% and 90% of patients with cancer had anemia. Prevalence was affected strongly by the definition of anemia: 7% of patients with Hodgkin disease had anemia when the condition was defined as a hemoglobin level <90.0 g/L; as many as 86% of patients had anemia when it was defined as a hemoglobin value <110.0 g/L. Prevalence varied by cancer type and disease stage: 40% of patients with early-stage colon tumors and nearly 80% of patients with advanced disease had anemia. Patients with anemia had poorer survival and local tumor control than did their nonanemic counterparts in 15 of 18 studies. In 8 of 12 studies, patients without anemia (most treated with epoetin) needed fewer transfusions. QOL was positively correlated with hemoglobin levels in 15 of 16 studies. There was no significant difference in treatment toxicity between patients with and without anemia. Tumor hypoxia, which has been associated with resistance to radiation therapy and chemotherapy, may stimulate angiogenesis, leading to poor local control of tumors and increased morbidity and mortality. Treatment of anemia may have a significant impact on patient survival and QOL. However, a standard definition of anemia is needed, as is research about the effect of anemia on cancer progression.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Littlewood T.J.
        The impact of hemoglobin levels on treatment outcomes in patients with cancer.
        Semin Oncol. 2001; 28: 49-53
        • Coiffier B.
        • Guastalla J.P.
        • Pujade-Lauraine E.
        • Bastit P.
        Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy.
        Eur J Cancer. 2001; 37: 1617-1623
        • Spivak J.L.
        Cancer-related anemia.
        Semin Oncol. 1994; 21: 3-8
        • Bron D.
        • Meuleman N.
        • Mascaux C.
        Biological basis of anemia.
        Semin Oncol. 2001; 28: 1-6
        • Henry D.H.
        Recombinant human erythropoietin treatment of anemic cancer patients.
        Cancer Pract. 1996; 4: 180-184
        • Fyles A.W.
        • Milosevic M.
        • Pintilie M.
        • Syed A.
        • Hill R.P.
        Anemia, hypoxia and transfusion in patients with cervix cancer.
        Radiother Oncol. 2000; 57: 13-19
        • Thomas G.M.
        Raising hemoglobin.
        Oncology. 2002; 63: 19-28
        • Song S.Z.
        • Sun Y.
        • Wang Y.P.
        • Zhang Z.G.
        • Niu F.E.
        Secondary hematologic changes in small cell lung cancer and malignant lymphoma.
        Chin Med J (Engl). 1987; 100: 97-102
        • Rassam J.W.
        • Anderson G.
        Incidence of paramalignant disorders in bronchogenic carcinoma.
        Thorax. 1975; 30: 86-90
        • Harrison L.B.
        • Shasha D.
        • White C.
        • Ramdeen B.
        Radiotherapy-associated anemia.
        Oncologist. 2000; 5: 1-7
        • Harrison L.B.
        • Shasha D.
        • Homel P.
        Prevalence of anemia in cancer patients undergoing radiotherapy.
        Oncology. 2002; 63: 11-18
        • Tchekmedyian N.S.
        Anemia in cancer patients.
        Oncology (Huntingt). 2002; 16: 17-24
        • Twine R.W.
        • Morris C.
        Early detection of carcinomas of the right colon.
        J Natl Med Assoc. 1986; 78: 187-192
        • Fass L.
        • Anderson F.W.
        • Young L.E.
        Delay in diagnosis of carcinoma of right side of colon in patients treated for anemia.
        Am J Med Sci. 1966; 251: 255-259
        • Dunne J.R.
        • Gannon C.J.
        • Osborn T.M.
        • Taylor M.D.
        • Malone D.L.
        • Napolitano L.M.
        Preoperative anemia in colon cancer.
        Am Surg. 2002; 68: 582-587
        • Cappell M.S.
        • Goldberg E.S.
        The relationship between the clinical presentation and spread of colon cancer in 315 consecutive patients.
        J Clin Gastroenterol. 1992; 14: 227-235
        • Dunphy E.P.
        • Petersen I.A.
        • Cox R.S.
        • Bagshaw M.A.
        The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 1989; 16: 1173-1178
        • Lee W.R.
        • Berkey B.
        • Marcial V.
        • et al.
        Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma.
        Int J Radiat Oncol Biol Phys. 1998; 42: 1069-1075
        • Dubray B.
        • Mosseri V.
        • Brunin F.
        • et al.
        Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer.
        Radiology. 1996; 201: 553-558
        • Grant D.G.
        • Hussain A.
        • Hurman D.
        Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy.
        J Laryngol Otol. 1999; 113: 829-833
        • von Knorring J.
        • Selroos O.
        • Scheinin T.M.
        Haematologic findings in patients with renal carcinoma.
        Scand J Urol Nephrol. 1981; 15: 279-283
        • Obermair A.
        • Petru E.
        • Windbichler G.
        • et al.
        Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer.
        Oncol Rep. 2000; 7: 639-644
        • Obralic N.
        • Bilenjki D.
        • Bilbija Z.
        Prognostic importance of anemia related parameters in patients with carcinoma of the cervix uteri.
        Acta Oncol. 1990; 29: 199-201
        • Hefler L.
        • Mayerhofer K.
        • Leibman B.
        • et al.
        Tumor anemia and thrombocytosis in patients with vulvar cancer.
        Tumour Biol. 2000; 21: 309-314
        • Ratkin G.A.
        • Presant C.A.
        • Weinerman B.
        • Reinhard E.H.
        Correlation of anemia with infradiaphragmatic involvement in Hodgkin's disease and other malignant lymphomas.
        CMAJ. 1974; 111: 924-927
        • Emanuel D.J.
        • Gelfand M.
        A survey into the clinical presentation of Hodgkin's disease at Harare Hospital, Salisbury, Rhodesia.
        J Trop Med Hyg. 1975; 78: 44-46
        • Bearman R.M.
        • Pangalis G.A.
        • Rappaport H.
        Hodgkin's disease, lymphocyte depletion type.
        Cancer. 1978; 41: 293-302
        • Pohl C.
        • Schobert I.
        • Moter A.
        • et al.
        Serum erythropoietin levels in patients with Hodgkin's lymphoma at the time of diagnosis.
        Ann Oncol. 1992; 3: 172-173
        • Lim E.J.
        • Peh S.C.
        Bone marrow and peripheral blood changes in non-Hodgkin's lymphoma.
        Singapore Med J. 2000; 41: 279-285
        • Michon J.
        Incidence of anemia in pediatric cancer patients in Europe.
        Med Pediatr Oncol. 2002; 39: 448-450
        • Morrow T.J.
        • Volpe S.
        • Gupta S.
        • Tannous R.E.
        • Fridman M.
        Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma.
        South Med J. 2002; 95: 889-896
        • Moullet I.
        • Salles G.
        • Ketterer N.
        • et al.
        Frequency and significance of anemia in non-Hodgkin's lymphoma patients.
        Ann Oncol. 1998; 9: 1109-1115
        • Kyle R.A.
        • Gertz M.A.
        • Witzig T.E.
        • et al.
        Review of 1027 patients with newly diagnosed multiple myeloma.
        Mayo Clin Proc. 2003; 78: 21-33
        • Nielsen O.J.
        • Brandt M.
        • Drivsholm A.
        The secretory erythropoietin response in patients with multiple myeloma and Waldenstrom's macroglobulinaemia.
        Scand J Clin Lab Invest. 1990; 50: 697-703
        • Hannisdal E.
        • Kildahl-Andersen O.
        • Grottum K.A.
        • Lamvik J.
        Prognostic factors in multiple myeloma in a population-based trial.
        Eur J Haematol. 1990; 45: 198-202
        • Advani S.H.
        • Soman C.S.
        • Talwalkar G.V.
        • Lyer Y.S.
        • Bhatia H.M.
        Multiple-myeloma.
        Indian J Cancer. 1978; 15: 55-61
        • Hill R.S.
        • Wilson J.D.
        Multiple myeloma. 2. A report on sixty-seven cases.
        N Z Med J. 1968; 67: 194-203
        • Dawson A.A.
        • Ogston D.
        Factors influencing the prognosis in myelomatosis.
        Postgrad Med J. 1971; 47: 635-638
        • Frommhold H.
        • Guttenberger R.
        • Henke M.
        The impact of blood hemoglobin content on the outcome of radiotherapy.
        Strahlenther Onkol. 1998; 174: 31-34
        • Fein D.A.
        • Lee W.R.
        • Hanlon A.L.
        • et al.
        Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.
        J Clin Oncol. 1995; 13: 2077-2083
        • Reed W.R.
        • Hussey D.H.
        • DeGowin R.L.
        Implications of the anemia of chronic disorders in patients anticipating radiotherapy.
        Am J Med Sci. 1994; 308: 9-15
        • Overgaard J.
        • Hansen H.S.
        • Jorgensen K.
        • Hjelm Hansen M.
        Primary radiotherapy of larynx and pharynx carcinoma—an analysis of some factors influencing local control and survival.
        Int J Radiat Oncol Biol Phys. 1986; 12: 515-521
        • Warde P.
        • O'Sullivan B.
        • Bristow R.G.
        • et al.
        T1/T2 glottic cancer managed by external beam radiotherapy.
        Int J Radiat Oncol Biol Phys. 1998; 41: 347-353
        • van Acht M.J.
        • Hermans J.
        • Boks D.E.
        • Leer J.W.
        The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma.
        Radiother Oncol. 1992; 23: 229-235
        • Tarnawski R.
        • Skladowski K.
        • Maciejewski B.
        Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx.
        Int J Radiat Oncol Biol Phys. 1997; 38: 1007-1011
        • Overgaard J.
        • Hansen H.S.
        • Andersen A.P.
        • et al.
        Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx.
        Int J Radiat Oncol Biol Phys. 1989; 16: 1065-1068
        • Hierlihy P.
        • Jenkin R.D.
        • Stryker J.A.
        Anemia as a prognostic factor in cancer of the cervix.
        CMAJ. 1969; 100: 1100-1102
        • Alexanian R.
        • Balcerzak S.
        • Bonnet J.D.
        • et al.
        Prognostic factors in multiple myeloma.
        Cancer. 1975; 36: 1192-1201
        • Chow E.
        • Danjoux C.E.
        • Pataki I.
        • et al.
        Effect of hemoglobin on radiotherapy response in children with medulloblastoma.
        Med Pediatr Oncol. 1999; 32: 395-397
        • Leitgeb C.
        • Pecherstorfer M.
        • Fritz E.
        • Ludwig H.
        Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.
        Cancer. 1994; 73: 2535-2542
        • Ludwig H.
        • Chott A.
        • Fritz E.
        • Krainer M.
        Increase of bone marrow cellularity during erythropoietin treatment in myeloma.
        Stem Cells. 1995; 13: 77-87
        • Ludwig H.
        • Fritz E.
        • Leitgeb C.
        • et al.
        Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors.
        Ann Oncol. 1993; 4: 161-167
        • Rapoport B.L.
        • Falkson H.C.
        • Falkson G.
        Prognostic factors affecting the survival of patients with multiple myeloma.
        S Afr Med J. 1991; 79: 65-67
        • Prognostic features in the third MRC myelomatosis trial
        Medical Research Council's Working Party on Leukaemia in Adults.
        Br J Cancer. 1980; 42: 831-840
        • Ludwig H.
        • Sundal E.
        • Pecherstorfer M.
        • et al.
        Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.
        Cancer. 1995; 76: 2319-2329
        • Ludwig H.
        • Pecherstorfer M.
        • Leitgeb C.
        • Fritz E.
        Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.
        Stem Cells. 1993; 11: 348-355
        • Heiss M.M.
        • Tarabichi A.
        • Delanoff C.
        • et al.
        Perisurgical erythropoietin application in anemic patients with colorectal cancer.
        Surgery. 1996; 119: 523-527
        • Abels R.
        Erythropoietin for anaemia in cancer patients.
        Eur J Cancer. 1993; 29: S2-S8
        • Abels R.I.
        Recombinant human erythropoietin in the treatment of the anaemia of cancer.
        Acta Haematol. 1992; 87: 4-11
        • Braga M.
        • Gianotti L.
        • Vignali A.
        • et al.
        Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract.
        Br J Surg. 1995; 82: 1637-1640
        • Dammacco F.
        • Castoldi G.
        • Rodjer S.
        Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma [published erratum appears in Br J Haematol. 2001;114:738].
        Br J Haematol. 2001; 113: 172-179
        • Osterborg A.
        • Brandberg Y.
        • Molostova V.
        • et al.
        Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies.
        J Clin Oncol. 2002; 20: 2486-2494
        • Scott S.N.
        • Boeve T.J.
        • McCulloch T.M.
        • et al.
        The effects of epoetin alfa on transfusion requirements in head and neck cancer patients.
        Laryngoscope. 2002; 112: 1221-1229
        • Osterborg A.
        • Boogaerts M.A.
        • Cimino R.
        • et al.
        for the European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study.
        Blood. 1996; 87: 2675-2682
        • Olsson A.M.
        • Svensson J.H.
        • Sundstrom J.
        • et al.
        Erythropoietin treatment in metastatic breast cancer—effects on Hb, quality of life and need for transfusion.
        Acta Oncol. 2002; 41: 517-524
        • Quirt I.
        • Robeson C.
        • Lau C.Y.
        • et al.
        Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
        J Clin Oncol. 2001; 19: 4126-4134
        • Cella D.
        The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale.
        Semin Hematol. 1997; 34: 13-19
        • Holzner B.
        • Kemmler G.
        • Greil R.
        • et al.
        The impact of hemoglobin levels on fatigue and quality of life in cancer patients.
        Ann Oncol. 2002; 13: 965-973
        • Lind M.
        • Vernon C.
        • Cruickshank D.
        • et al.
        The level of haemoglobin in anaemic cancer patients correlates positively with quality of life.
        Br J Cancer. 2002; 86: 1243-1249
        • Ludwig H.
        • Fritz E.
        • Kotzmann H.
        • et al.
        Erythropoietin treatment of anemia associated with multiple myeloma.
        N Engl J Med. 1990; 322: 1693-1699
        • Falkson C.I.
        • Keren-Rosenberg S.
        • Uys A.
        • et al.
        Recombinant human erythropoietin in the treatment of cancer-related anaemia.
        Oncology. 1994; 51: 497-501
        • Glimelius B.
        • Linne T.
        • Hoffman K.
        • et al.
        Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.
        J Clin Oncol. 1998; 16: 434-440
        • Sweeney P.J.
        • Nicolae D.
        • Ignacio L.
        • et al.
        Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy.
        Br J Cancer. 1998; 77: 1996-2002
        • Henke M.
        • Bechtold C.
        • Momm F.
        • et al.
        Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues.
        Int J Radiat Oncol Biol Phys. 2000; 48: 339-345